Publications by authors named "M Vilbert"
Background: Trastuzumab deruxtecan (T-DXd) has shown promising activity in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and central nervous system (CNS) involvement. In this updated meta-analysis, we explore the effectiveness of T-DXd in a large subset of patients with HER2-positive BC and CNS disease.
Methods: A systematic search was made on September 16th, 2024, for studies investigating T-DXd in the scenario of HER2-positive BC and brain metastases (BMs) and/or leptomeningeal disease (LMD).
Purpose: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) combined with endocrine therapy (ET) are the standard of care in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (aBC). Yet, disease progression remains common. In the absence of established postprogression sequencing guidelines, we conducted a pooled analysis of Kaplan-Meier (KM)-derived patient data to assess the efficacy of subsequent treatment options after disease progression on CDK4/6i therapy.
View Article and Find Full Text PDFArticle Synopsis
- Sacituzumab Govitecan (SG) has shown significant clinical benefits for breast cancer patients but is associated with considerable toxicity.
- A meta-analysis of seven studies included 928 patients on SG and highlighted high rates of adverse events, particularly neutropenia (70%) and grade ≥3 neutropenia (46%).
- The findings suggest a need for careful monitoring and management of side effects when using SG, as it poses a higher risk of neutropenia, diarrhea, and anemia compared to standard treatment options.
Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis.
JCO Precis Oncol
November 2024
Article Synopsis
- A systematic review and meta-analysis were conducted to evaluate the safety and efficacy of osimertinib in non-small-cell lung cancer (NSCLC) patients with uncommon epidermal growth factor receptor mutations.
- The analysis included 15 studies with 594 patients, revealing common mutations such as G719X and L861Q, and determining key metrics like a 51.30% objective response rate (ORR) and a median progression-free survival of 9.71 months.
- Osimertinib was found to be generally safe, with only 21.77% of patients experiencing serious adverse events, showing promise for treating NSCLC with these uncommon mutations.